Ads
related to: hiv protein inhibitors- Download Patient Brochure
Find Resources With Important Info
About Treatment And Switching.
- HIV Real Patient Stories
Watch The Stories Of People Who
Share Their Treatment Experiences.
- HIV Treatment FAQs
Find Answers To Frequently Asked
Questions About HIV And Medication.
- Patient Assistance Info
Discover If You Are Eligible To
Save On An HIV-1 Treatment Option.
- Learn How Treatment Works
Visit The Patient Website To Learn
How An HIV-1 Treatment Works.
- Sign Up For More Info
Learn About An HIV Treatment Option
Sign Up To Receive Information.
- Download Patient Brochure
Search results
Results From The WOW.Com Content Network
These protease inhibitors prevent viral replication by selectively binding to viral proteases (e.g. HIV-1 protease) and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Protease inhibitors that have been developed and are currently used in clinical practice include:
Tipranavir is a nonpeptidic HIV-1 protease inhibitor [11] and reached the market in 2005. [18] Unlike other HIV protease inhibitors on the market, tipranavir was developed from a nonpeptidic coumarin template and its antiprotease activity was discovered by high-throughput screening. [23]
Phage display was used to identify peptides that bind the HIV-1 capsid protein, and the most promising peptide inhibitor was the Capsid Assembly Inhibitor (CAI) peptide. [17] CAI prevented the formation of mature capsids, but its poor permeability in cells limited its use. [17]
Several protease inhibitors have been licensed for HIV therapy. [19] There are ten HIV-1 PR inhibitors that are currently approved by the Food and Drug Administration: indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, amprenavir, fosamprenevir, atazanavir, tipranavir, and darunavir. Many of the inhibitors have different molecular ...
Griffithsin, a substance derived from algae, appears to have entry inhibitor properties. [7] DCM205, is a small molecule based on L-chicoric acid, an integrase inhibitor. DCM205 has been reported to inactivate HIV-1 particles directly in vitro and is thought to act primarily as an entry inhibitor. [8]
The maturation inhibitors are a class of antiviral drugs for the treatment of infection with HIV.They act by interfering with the maturation of the virus. Specifically, drugs in this class disrupt the final step in the processing of the HIV-1 gag protein, the cleavage of its immediate precursor by the enzyme HIV-1 protease.
Ads
related to: hiv protein inhibitors